Nanotechnology - a Robust Tool for Fighting the Challenges of Drug Resistance in Non-small Cell Lung Cancer

Overview

Journal Beilstein J Nanotechnol

Specialty Biotechnology

Date 2023 Mar 3

PMID 36865093

Authors

Filip Gorachinov

Fatima Mraiche

Diala Alhaj Moustafa

Ola Hishari

Yomna Ismail

Jensa Joseph

Maja Simonoska Crcarevska

Marija Glavas Dodov

Nikola Geskovski

Katerina Goracinova

Affiliations

Soon will be listed here.

Abstract

Genomic and proteomic mutation analysis is the standard of care for selecting candidates for therapies with tyrosine kinase inhibitors against the human epidermal growth factor receptor (EGFR TKI therapies) and further monitoring cancer treatment efficacy and cancer development. Acquired resistance due to various genetic aberrations is an unavoidable problem during EGFR TKI therapy, leading to the rapid exhaustion of standard molecularly targeted therapeutic options against mutant variants. Attacking multiple molecular targets within one or several signaling pathways by co-delivery of multiple agents is a viable strategy for overcoming and preventing resistance to EGFR TKIs. However, because of the difference in pharmacokinetics among agents, combined therapies may not effectively reach their targets. The obstacles regarding the simultaneous co-delivery of therapeutic agents at the site of action can be overcome using nanomedicine as a platform and nanotools as delivery agents. Precision oncology research to identify targetable biomarkers and optimize tumor homing agents, hand in hand with designing multifunctional and multistage nanocarriers that respond to the inherent heterogeneity of the tumors, may resolve the challenges of inadequate tumor localization, improve intracellular internalization, and bring advantages over conventional nanocarriers.

Citing Articles

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.

PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.

Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.

Crintea A, Constantin A, Motofelea A, Crivii C, Velescu M, Coseriu R J Funct Biomater. 2023; 14(9).

PMID: 37754880 PMC: 10532491. DOI: 10.3390/jfb14090466.

References

Kallu J, Banerjee T, Sulthana S, Darji S, Higginbotham R, Fletcher C . Nanomedicine-Assisted Combination Therapy of NSCLC: New Platinum-Based Anticancer Drug Synergizes the Therapeutic Efficacy of Ganetespib. Nanotheranostics. 2019; 3(1):120-134. PMC: 6427934. DOI: 10.7150/ntno.28468. View

Hartl M . The Quest for Targets Executing MYC-Dependent Cell Transformation. Front Oncol. 2016; 6:132. PMC: 4889588. DOI: 10.3389/fonc.2016.00132. View

Perepelyuk M, Shoyele O, Birbe R, Thangavel C, Liu Y, Den R . siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. Mol Ther Nucleic Acids. 2017; 6:259-268. PMC: 5363504. DOI: 10.1016/j.omtn.2016.12.009. View

Comunanza V, Bussolino F . Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Front Cell Dev Biol. 2017; 5:101. PMC: 5725406. DOI: 10.3389/fcell.2017.00101. View

Westover D, Zugazagoitia J, Cho B, Lovly C, Paz-Ares L . Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018; 29(suppl_1):i10-i19. PMC: 6454547. DOI: 10.1093/annonc/mdx703. View

Wang Y, Tian P, Xia L, Li L, Han R, Zhu M . The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. Lung Cancer. 2020; 146:165-173. DOI: 10.1016/j.lungcan.2020.06.003. View

Chen G, Kronenberger P, Teugels E, Umelo I, De Greve J . Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012; 10:28. PMC: 3334713. DOI: 10.1186/1741-7015-10-28. View

Alvarez M, Simonetta F, Baker J, Morrison A, Wenokur A, Pierini A . Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion. Front Immunol. 2020; 11:7. PMC: 7026672. DOI: 10.3389/fimmu.2020.00007. View

Takeda M, Nakagawa K . First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive Mutation-Positive Non-Small Cell Lung Cancer?. Int J Mol Sci. 2019; 20(1). PMC: 6337322. DOI: 10.3390/ijms20010146. View

10.

Shen J, Yin Q, Chen L, Zhang Z, Li Y . Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials. 2012; 33(33):8613-24. DOI: 10.1016/j.biomaterials.2012.08.007. View

11.

Yao Y, Peng M, Shen Q, Hu Q, Gong H, Li Q . Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples. Thorac Cancer. 2018; 10(2):193-202. PMC: 6360205. DOI: 10.1111/1759-7714.12932. View

12.

Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C . Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2022; 119(8). PMC: 8872770. DOI: 10.1073/pnas.2116271119. View

13.

Salgia R . Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn. 2016; 16(7):737-49. PMC: 4926789. DOI: 10.1080/14737159.2016.1181545. View

14.

Yan Y, Xiong H, Zhang X, Cheng Q, Siegwart D . Systemic mRNA Delivery to the Lungs by Functional Polyester-based Carriers. Biomacromolecules. 2017; 18(12):4307-4315. DOI: 10.1021/acs.biomac.7b01356. View

15.

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View

16.

Qiu G, Xue L, Zhu X, Lu X, Liu L, Wang Z . Cetuximab Combined With Sonodynamic Therapy Achieves Dual-Modal Image Monitoring for the Treatment of EGFR-Sensitive Non-Small-Cell Lung Cancer. Front Oncol. 2022; 12:756489. PMC: 8886674. DOI: 10.3389/fonc.2022.756489. View

17.

Zhu Y, Lin X, Li X, Wu L, Chen H, Wang W . Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review. Thorac Cancer. 2017; 9(1):159-163. PMC: 5754306. DOI: 10.1111/1759-7714.12518. View

18.

Sulthana S, Banerjee T, Kallu J, Vuppala S, Heckert B, Naz S . Combination Therapy of NSCLC Using Hsp90 Inhibitor and Doxorubicin Carrying Functional Nanoceria. Mol Pharm. 2017; 14(3):875-884. PMC: 6741431. DOI: 10.1021/acs.molpharmaceut.6b01076. View

19.

Tasciotti E, Liu X, Bhavane R, Plant K, Leonard A, Price B . Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol. 2008; 3(3):151-7. DOI: 10.1038/nnano.2008.34. View

20.

Masood A, Kancha R, Subramanian J . Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Semin Oncol. 2019; 46(3):271-283. DOI: 10.1053/j.seminoncol.2019.08.004. View